Filing Summary
Company: Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)
Reporting event: Form 8-K filed October 16, 2026, reporting results of the company’s annual meeting held that day.
Business Context and Reporting Period
This filing reports stockholder voting results, not quarterly or annual operating results. The record date was August 20, 2026. Of 5,471,297 common shares outstanding and entitled to vote, 2,890,899 shares were represented, approximately 52.83%, establishing a quorum.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Meeting Results
| Proposal | Result |
|---|---|
| Election of Class II directors | David P. Luci was elected with 1,187,323 votes for, 73,804 withheld, and 1,629,772 broker non-votes. Jack H. Dean was elected with 1,203,310 votes for, 57,817 withheld, and 1,629,772 broker non-votes. Both directors will serve terms expiring in 2029. |
| Ratification of independent auditor | Stockholders ratified CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026: 2,877,193 votes for, 8,473 against, and 5,233 abstentions. |
Outlook, Risks, and Unusual Items
The filing provides no financial guidance, management outlook, or discussion of business risks or contingencies.
Important Facts for Investors to Verify
- Confirm the directors’ election and their terms expiring in 2029.
- Confirm CohnReznick LLP’s ratification as auditor for fiscal 2026.
- Consult the definitive proxy statement filed September 1, 2026, for proposal details and related disclosures.